Imiquimod (hydrochloride)

Imiquimod (hydrochloride)

• CAS Number: 99011-78-6
• UNSPSC Description: Imiquimod hydrochloride (R 837 hydrochloride), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod hydrochloride exhibits antiviral and antitumor effects in vivo. Imiquimod hydrochloride can be used for the research of external genital, perianal warts, cancer and COVID-19[1][2].
• Target Antigen: Autophagy; HSV; SARS-CoV; Toll-like Receptor (TLR)
• Type: Reference compound
• Related Pathways: Anti-infection;Autophagy;Immunology/Inflammation
• Applications: COVID-19-anti-virus
• Field of Research: Cancer; Infection; Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/imiquimod-hydrochloride.html
• Purity: 99.77
• Solubility: DMSO : 8 mg/mL (ultrasonic;warming;heat to 50°C)|Ethanol : 3.85 mg/mL (ultrasonic)|H2O : 8.33 mg/mL (ultrasonic)|Methanol : 24 mg/mL (ultrasonic)
• Smiles: NC1=NC2=CC=CC=C2C3=C1N=CN3CC(C)C.Cl
• Molecular Weight: 276.76
• References & Citations: [1]Athina Angelopoulou, et al. Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19. Environ Res. 2020 Sep; 188: 109858.|[2]Michael P Schön, et al. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. J Invest Dermatol. 2006 Jun;126(6):1338-47.|[3]Aditya K Gupta, et al. Imiquimod: a review. J Cutan Med Surg. Nov-Dec 2002;6(6):554-60.|[4]Yuji Kan, et al. Imiquimod suppresses propagation of herpes simplex virus 1 by upregulation of cystatin A via the adenosine receptor A1 pathway. J Virol. 2012 Oct;86(19):10338-46.bioRxiv. 2024 Apr 20.|Cell Rep Methods. 2023 Oct 23;3(10):100599.|Int J Pharm. 2023 Nov 7:648:123583.|J Nanobiotechnology. 2023 Feb 10;21(1):50.|Nat Commun. 2022 Jul 22;13(1):4255.|Nucleic Acids Res. 2021 Jan 8;49(D1):D1113-D1121.|protocols.io. 2024 Apr 13.|Virulence. 2023 Dec;14(1):2223394.|ACS Appl Bio Mater. 2019, 2, 874-883.|Acta Pharm Sin B. 2024 Jun 20.|Adv Sci (Weinh). 2024 Jul 17:e2405158.|Am J Respir Cell Mol Biol. 2022 Oct 13.|Biochem Biophys Res Commun. 2024 Feb 15, 149661.|Biomaterials. 2021, 120724.|Biomaterials. 2022 Feb 14;282:121411.|Cell Commun Signal. 2023 Aug 18;21(1):215.|Cell Rep. 2021 Feb 2;34(5):108724.|Diam Relat Mater. 2023 May 26, 110058.|Drug Deliv. 2023 Dec;30(1):2183814.|EMBO Rep. 2022 Feb 3;23(2):e53499.|FEBS Lett. 2021 Aug 13.|Int Immunopharmacol. 2024 Sep 21;142(Pt B):113190.|J Agric Food Chem. 2024 Jan 3.|J Cell Mol Med. 2024 Apr;28(8):e18356.|J Control Release. 2023 Aug 12;361:443-454.|J Ethnopharmacol. 2024 Jan 2:117711.|J Invest Dermatol. 2021 Oct 20;S0022-202X(21)02369-1.|J Nanobiotechnology. 2022 May 14;20(1):228.|MedComm. 04 March 2022.|Nat Commun. 2016 May 25;7:11724. |Nucleic Acids Res. 2021 Jan 8;49(D1):D1113-D1121.|Oxid Med Cell Longev. 12 Oct 2022.|Preprints. 2024 Aug 27.|Research Square Preprint. 2021 Oct.|Research Square Preprint. 2023 Nov 17.|Research Square Print. 2023 Feb 1.|Sci Rep. 2024 Mar 4;14(1):5237.|Theranostics. 2023 Apr 9;13(7):2226-2240.|Nucleic Acids Res. 2021 Jan 8;49(D1):D1113-D1121.|Pharmacol Res. 2023 Nov 24:198:107016.
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, sealed storage, away from moisture)
• Clinical Information: Launched